文献速递基础与转化研究新药、器械与细胞基因治疗研发

碱基编辑β0-地中海贫血突变作为重型β-血红蛋白病的治疗策略

Base editing of β0-thalassemia mutations as a therapeutic strategy for severe β-hemoglobinopathies.
PubMed 文献 · Sci Transl Med · 2025-11-26

临床前研究采用高持续活性腺嘌呤碱基编辑变体(NRCH-ABE8e和SpRY-ABE8e)精准校正HBB基因中CD39和IVS2-1等常见重型β-地中海贫血突变。造血干/祖细胞编辑效率超过90%,红系子代β-珠蛋白表达改善,β-地中海贫血和镰状细胞β-地中海贫血表型持续校正。体外和体内实验未发现基因失调或DNA突变负荷、RNA脱氨、β-珠蛋白基因座完整性及移植物克隆性的有意义影响。

要点

  • NRCH-ABE8e和SpRY-ABE8e分别精准校正HBB基因CD39和IVS2-1突变。
  • 造血干/祖细胞编辑效率超过90%,红系子代β-珠蛋白表达改善。
  • 临床前研究提示该策略可能安全有效,未发现基因失调或有意义影响。

核心结论

  • 这些临床前研究提示碱基编辑介导的基因校正可能是治疗β-血红蛋白病的一种安全有效策略。

研究设计与样本

  • 临床前研究,使用高持续活性腺嘌呤碱基编辑变体NRCH-ABE8e和SpRY-ABE8e分别校正HBB基因CD39和IVS2-1突变,在造血干/祖细胞中进行体外编辑及免疫缺陷小鼠移植实验。

主要发现

  • 造血干/祖细胞编辑效率超过90%,其红系子代β-珠蛋白表达改善,β-地中海贫血和镰状细胞β-地中海贫血表型持续校正。
  • 体外和体内实验通过RNA测序、全外显子组测序、长读长测序及人造血干/祖细胞移植免疫缺陷小鼠评估,未发现基因失调或对DNA突变负荷、RNA脱氨、β-珠蛋白基因座完整性及造血干/祖细胞移植物克隆性的有意义影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gene therapy has emerged as a promising curative treatment for β-hemoglobinopathies, the most common genetic disorders worldwide. However, current approved approaches still have some limitations in terms of safety and efficacy. Here, we used highly processive adenine base editor (ABE) variants to precisely correct some of the most prevalent and severe β-thalassemia-causing mutations in the β-globin-encoding HBB gene, including CD39 and IVS2-1, using NRCH-ABE8e and SpRY-ABE8e, respectively. More than 90% of editing of hematopoietic stem and progenitor cells (HSPCs) led to improved β-globin expression in their erythroid progeny and persistent correction of both β-thalassemia and sickle cell-β-thalassemia phenotypes. The safety of this strategy was confirmed in HSPCs in vitro and in vivo through the absence of gene dysregulation and any meaningful impact on the DNA mutational burden, RNA deamination, β-globin gene locus integrity, and the clonality of the HSPC graft, as assessed by RNA sequencing, whole-exome sequencing, long-read sequencing, and human HSPC transplantation in immunodeficient mice. Overall, these preclinical studies suggest that base editing-mediated gene correction may be a safe and effective strategy for treating β-hemoglobinopathies.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Hardouin G, Martinucci P, Scaramuzza S, et al. Base editing of β0-thalassemia mutations as a therapeutic strategy for severe β-hemoglobinopathies. Sci Transl Med. 2025. PMID: 41296828. doi:10.1126/scitranslmed.adt8617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。